Skip to main content

Risperdal Plaintiff Allowed To Replead A Negligent Claim

Risperdal Plaintiff Allowed To Replead A Negligent Claim

Risperdal Plaintiff Allowed To Replead A Negligent Claim

Introduction

In an order issued on September 30, 2018, Judge Donald Cabell of the U.S. District Court for the District of Massachusetts, allowed the plaintiff to replead his negligent failure-to-warn claims linked to Risperdal side-effects. However, claims of consumer law violations, fraudulent concealment, and design defect against defendants Janssen Research & Development and Johnson & Johnson were dismissed.

The plaintiff started consuming Risperdal medication in 2007 to treat his personality disorder; however, he developed gynecomastia (increased breast tissue) and tremors as an alleged side-effect of the drug. Even after stopping the medication in 2016, the gynecomastia condition still prevailed.

More than 14,000 lawsuits have been filed over the drugs' gynecomastia side-effect. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Last month, a $1 million Risperdal verdict was overturned indicating that the failure-to-warn claim made by a man against Janssen Pharmaceuticals stays preempted since the federal law bars the company from adding a gynecomastia warning label. The federal judge also stated that the ruling was passed considering the plaintiff's attorney's "inappropriate conduct" evident from his defensive tone of voice during the court hearing.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.